Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
Current and future development in lung cancer diagnosis
R Nooreldeen, H Bach - International journal of molecular sciences, 2021 - mdpi.com
Lung cancer is the leading cause of cancer-related deaths in North America and other
developed countries. One of the reasons lung cancer is at the top of the list is that it is often …
developed countries. One of the reasons lung cancer is at the top of the list is that it is often …
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and …
Background Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified
through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune …
through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of
RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate …
RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate …
Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227
JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
[HTML][HTML] First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial
LG Paz-Ares, SS Ramalingam, TE Ciuleanu… - Journal of Thoracic …, 2022 - Elsevier
Abstract Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …
Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non–small-cell lung cancer previously treated with …
KL Reckamp, MW Redman, KH Dragnev… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell
lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular …
lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular …